Related Experiment Video
Updated: May 21, 2026
Development and Assessment of Intracellular Infection Models for Staphylococcus aureus
Published on: January 17, 2025
Liposomal encapsulation of vancomycin improves killing of methicillin-resistant Staphylococcus aureus in a murine
Linette Sande1, Marisel Sanchez, Joy Montes
1Division of Pediatric Infectious Diseases, David Geffen School of Medicine, Mattel Children's Hospital UCLA, Los Angeles, CA 90095, USA.
Objectives:
Methicillin-resistant Staphylococcus aureus (MRSA) poses a major problem to public health worldwide. MRSA strains with increased resistance to vancomycin cause infections that are associated with greater morbidity and threaten the use of this once gold-standard antistaphylococcal drug. We investigated whether encapsulation of vancomycin within liposomes could improve its antistaphylococcal activity.
Methods:
Two liposomal formulations of vancomycin were prepared using a rehydration-dehydration method. MICs and MBCs of the liposomal vancomycin for strains of MRSA were determined. The efficacy of one of the liposomal vancomycin formulations was also investigated in a time-kill assay in vitro and in a murine systemic infection model.
Results:
Encapsulation in either liposome preparation decreased the vancomycin MICs and MBCs for MRSA strains by approximately 2-fold. Liposomal vancomycin increased killing of MRSA in vitro in a kinetic study. In a systemic murine infection model, treatment with a 50 mg/kg intraperitoneal injection of liposomal vancomycin improved kidney clearance of a USA300 strain by 1 log compared with an injection of 50 mg/kg of free vancomycin.
Conclusions:
Our findings suggest that entrapment within liposomes could improve the antistaphylococcal efficacy of vancomycin.
Insights
Liposomal vancomycin shows improved activity against methicillin-resistant Staphylococcus aureus (MRSA). Encapsulating vancomycin in liposomes enhances its efficacy in vitro and in a murine infection model, offering a potential strategy against resistant bacterial infections.
Area of Science:
- Pharmacology
- Microbiology
- Drug Delivery Systems
Background:
- Methicillin-resistant Staphylococcus aureus (MRSA) is a significant global public health threat.
- Increasing vancomycin resistance in MRSA complicates treatment and necessitates novel therapeutic approaches.
Purpose of the Study:
- To evaluate the enhanced antistaphylococcal activity of vancomycin encapsulated within liposomes.
- To determine if liposomal vancomycin improves efficacy against MRSA strains.
Main Methods:
- Two liposomal vancomycin formulations were prepared using a rehydration-dehydration method.
- Minimum inhibitory concentrations (MICs) and minimum bactericidal concentrations (MBCs) were determined for MRSA strains.
- In vitro time-kill assays and a murine systemic infection model were used to assess efficacy.
Main Results:
- Liposomal vancomycin demonstrated approximately a 2-fold decrease in vancomycin MICs and MBCs against MRSA.
- Liposomal vancomycin enhanced the killing of MRSA in vitro.
- In a murine model, liposomal vancomycin improved kidney clearance of a USA300 MRSA strain by 1 log compared to free vancomycin.
Conclusions:
- Entrapment of vancomycin within liposomes enhances its antistaphylococcal efficacy.
- Liposomal vancomycin represents a promising strategy to combat MRSA infections.
- This approach may help preserve the utility of vancomycin as a critical antibiotic.
More Related Videos
Related Concept Videos
01:25Clinical Significance of Antibiotic Resistance
01:25Mechanism of Antibiotic Resistance in MRSA
01:23Inhibitors of Gram-positive Cell Wall Synthesis